{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Tumor assessment was performed using mINRC for Participants with Neuroblastoma.","groups":[{"description":"Participants with Neuroblastoma.","id":"OG000","title":"Neuroblastoma"}],"paramType":"NUMBER","populationDescription":"The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.","reportingStatus":"POSTED","timeFrame":"Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)","title":"Percentage of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) for Participants With Neuroblastoma (Phase I)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}